List of Tables 8
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
Ovarian Cancer Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Ovarian Cancer 16
Ovarian Cancer Therapeutics under Development by Companies 18
Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 39
Comparative Analysis 39
Mid Clinical Stage Products 40
Comparative Analysis 40
Early Clinical Stage Products 41
Comparative Analysis 41
Discovery and Pre-Clinical Stage Products 42
Comparative Analysis 42
Ovarian Cancer Therapeutics – Products under Development by Companies 43
Ovarian Cancer Therapeutics – Products under Investigation by
Universities/Institutes 58
Companies Involved in Ovarian Cancer Therapeutics Development 89
Johnson & Johnson 89
Boehringer Ingelheim GmbH 90
F. Hoffmann-La Roche Ltd. 91
Abbott Laboratories 92
Amgen Inc. 93
Sanofi-Aventis 94
AstraZeneca PLC 95
Eli Lilly and Company 96
Viralytics Ltd. 97
GlaxoSmithKline plc 98
Tekmira Pharmaceuticals Corp. 99
Genentech, Inc. 100
Nektar Therapeutics 101
Daiichi Sankyo Company, Ltd 102
Merck & Co., Inc. 103
Micromet, Inc. 104
Generex Biotechnology Corporation 105
Takeda Pharmaceutical Company Limited 106
Bio-Path Holdings, Inc. 107
Millennium Pharmaceuticals, Inc. 108
Novartis AG 109
Viventia Biotechnologies Inc. 198
TRACON Pharmaceuticals, Inc. 199
Advanced Cancer Therapeutics 200
Oncolix, Inc. 201
OHR Pharmaceutical Inc. 202
RECEPTA Biopharma S.A. 203
Kyowa Hakko Kirin Pharma, Inc. 204
Vaxonco 205
Sentinel Oncology Limited 206
Mebiopharm Co., Ltd. 207
VectorLogics, Inc. 208
ISA Pharmaceuticals B.V. 209
Gradalis Inc. 210
Oncozyme Pharma Inc. 211
Ovarian Cancer – Therapeutics Assessment 212
Assessment by Monotherapy Products 212
Assessment by Combination Products 213
Assessment by Route of Administration 214
Assessment by Molecule Type 217
Drug Profiles 220
AMG 386 - Drug Profile 220
Abagovomab - Drug Profile 222
OPAXIO - Drug Profile 223
MORAb-003 - Drug Profile 225
Paclical - Drug Profile 227
Telcyta - Drug Profile 229
NV06 - Drug Profile 231
Vargatef - Drug Profile 232
Tirazone - Drug Profile 234
Particulate Delivery - Drug Profile 235
Trabectedin - Drug Profile 236
Carboplatin + Thalidomide - Drug Profile 237
Amifostine Trihydrate - Drug Profile 238
Phenoxodiol + Carboplatin - Drug Profile 239
Bevacizumab + Carboplatin + Gemcitabine - Drug Profile 240
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 242
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 244
Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile 246
Carboplatin + Taxol - Drug Profile 248
Cisplatin + Taxol - Drug Profile 249
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 250
Carboplatin + Paclitaxel - Drug Profile 252
Paclitaxel + Carboplatin + Topotecan - Drug Profile 255
Carboplatin + Ifosfamide - Drug Profile 257
Carboplatin + Ifosfamide + Whole Body Hyperthermia - Drug Profile 259
Carboplatin + Paclitaxel + Cediranib - Drug Profile 261
Carboplatin + Paclitaxel + Doxorubicin HCl Liposome - Drug Profile 263
Carboplatin + Paclitaxel + Gemcitabine - Drug Profile 265
Carboplatin + Topotecan Hydrochloride - Drug Profile 267
Carboplatin + Gemcitabine - Drug Profile 269
Carboplatin + Paclitaxel - Drug Profile 271
Carboplatin - Drug Profile 273
Bevacizumab + Carboplatin + Docetaxel + Paclitaxel - Drug Profile 274
Sodium Thiosulfate - Drug Profile 275
Paclitaxel - Drug Profile 276
Taxol + Paraplatin - Drug Profile 277
AMG 386 + Pegylated Liposomal Doxorubicin - Drug Profile 279
AMG 386 + Paclitaxel - Drug Profile 280
Carboplatin + Paclitaxel - Drug Profile 281
Treosulfan - Drug Profile 283
Carboplatin + Gemcitabine Hydrochloride + Paclitaxel - Drug Profile 284
Carboplatin + Liposomal Doxorubicin - Drug Profile 286
Ifosfamide + Paclitaxel - Drug Profile 287
Yondelis + DOXIL - Drug Profile 289
Avastin + Carboplatin + Paclitaxel - Drug Profile 290
Avastin + Carboplatin + Paclitaxel - Drug Profile 292
Avastin + Paclitaxel + Topotecan + Liposomal Doxorubicin - Drug Profile 294
Gemcitabine + Carboplatin - Drug Profile 295
Telcyta + Paraplatin - Drug Profile 297
Topotecan - Drug Profile 299
Karenitecin - Drug Profile 300
CAELYX + Carboplatin - Drug Profile 301
Paclitaxel + Carboplatin - Drug Profile 302
Doxorubicin + Carboplatin + Paclitaxel - Drug Profile 303
Cisplatin - Drug Profile 305
Cyclophosphamide + Cisplatin - Drug Profile 306
Bevacizumab + Cisplatin + Paclitaxel - Drug Profile 307
EC145 + Doxil - Drug Profile 309
Cisplatin - Drug Profile 310
Cisplatin + Carboplatin - Drug Profile 311
Avastin - Drug Profile 313
Filgrastim + Doxorubicin + Ifosfamide - Drug Profile 314
Doxorubicin + Carboplatin - Drug Profile 316
Paclitaxel + Carboplatin - Drug Profile 317
Docetaxel + Carboplatin - Drug Profile 318
Paclitaxel + Carboplatin - Drug Profile 319
Oxaliplatin + Capecitabine - Drug Profile 320
Carboplatin + Taxol - Drug Profile 321
Irinotecan + Cisplatin - Drug Profile 323
Irinotecan + Cisplatin - Drug Profile 325
Taxol + Paraplatin + Bevacizumab - Drug Profile 326
cediranib - Drug Profile 328
Paclitaxel + Carboplatin + Epirubicin - Drug Profile 329
Irinotecan + Cisplatin - Drug Profile 331
Votrient - Drug Profile 332
Tarceva - Drug Profile 334
Paclitaxel + AZD0530 - Drug Profile 336
Cisplatin + Cyclophosphamide + Tamoxifen - Drug Profile 337
Bevacizumab + Carboplatin + Paclitaxel - Drug Profile 339
Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile 341
OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile 342
Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile 344
Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile 346
Carboplatin + Glutathione + Paclitaxel - Drug Profile 347
bevacizumab + capecitabine + carboplatin + oxaliplatin + paclitaxel - Drug
Profile 349
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 352
Cisplatin + Paclitaxel - Drug Profile 354
CT-2103 - Drug Profile 355
Cisplatin + Taxol - Drug Profile 357
Cisplatin + Adriamycin - Drug Profile 358
Pegylated Liposomal Doxorubicin + Trabectedin - Drug Profile 359
Ovarian Cancer Therapeutics – Drug Profile Updates 360
Ovarian Cancer Therapeutics – Discontinued Products 368
Ovarian Cancer Therapeutics - Dormant Products 374
Ovarian Cancer – Product Development Milestones 401
Featured News & Press Releases 401
Appendix 410
Methodology 410
Expert Panel Validation 411
Contact Us 411
Disclaimer 411
List of Tables
Number of Products Under Development for Ovarian Cancer, H1 2012 23
Products under Development for Ovarian Cancer – Comparative Analysis, H1 2012 24
Number of Products under Development by Companies, H1 2012 26
Number of Products under Investigation by Universities/Institutes, H1 2012 36
Comparative Analysis by Late Stage Development, H1 2012 46
Comparative Analysis by Mid Clinical Stage Development, H1 2012 47
Comparative Analysis by Early Clinical Stage Development, H1 2012 48
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 49
Products under Development by Companies, H1 2012 50
Products under Investigation by Universities/Institutes, H1 2012 65
Johnson & Johnson, H1 2012 96
Boehringer Ingelheim GmbH, H1 2012 97
F. Hoffmann-La Roche Ltd., H1 2012 98
Abbott Laboratories, H1 2012 99
Amgen Inc., H1 2012 100
Sanofi-Aventis, H1 2012 101
AstraZeneca PLC, H1 2012 102
Eli Lilly and Company, H1 2012 103
Viralytics Ltd., H1 2012 104
GlaxoSmithKline plc, H1 2012 105
Tekmira Pharmaceuticals Corp., H1 2012 106
Genentech, Inc., H1 2012 107
Nektar Therapeutics, H1 2012 108
Daiichi Sankyo Company, Ltd, H1 2012 109
Merck & Co., Inc., H1 2012 110
Micromet, Inc., H1 2012 111
Generex Biotechnology Corporation, H1 2012 112
Takeda Pharmaceutical Company Limited, H1 2012 113
Bio-Path Holdings, Inc., H1 2012 114
Millennium Pharmaceuticals, Inc., H1 2012 115
Novartis AG, H1 2012 116
Samyang Corporation, H1 2012 117
Aphios Corporation, H1 2012 118
ImClone Systems Incorporated, H1 2012 119
Eisai Co., Ltd., H1 2012 120
ImmunoGen, Inc., H1 2012 121
OSI Pharmaceuticals, Inc., H1 2012 122
Cell Therapeutics, Inc., H1 2012 123
Santaris Pharma A/S, H1 2012 124
Exelixis, Inc., H1 2012 125
Aduro BioTech, H1 2012 126
TopoTarget A/S, H1 2012 151
Karolinska Institutet, H1 2012 152
Poniard Pharmaceuticals, Inc., H1 2012 153
Oncogenex Pharmaceuticals, Inc., H1 2012 154
Dendreon Corporation, H1 2012 155
Thallion Pharmaceuticals Inc., H1 2012 156
Prima BioMed Limited, H1 2012 157
PharmaGap Inc., H1 2012 158
Quest PharmaTech Inc., H1 2012 159
Synta Pharmaceuticals Corp., H1 2012 160
Oasmia Pharmaceutical AB, H1 2012 161
Algeta ASA, H1 2012 162
RXi Pharmaceuticals Corporation, H1 2012 163
Rexahn Pharmaceuticals, Inc., H1 2012 164
MabVax Therapeutics, Inc., H1 2012 165
Morphotek, Inc., H1 2012 166
Oryzon, H1 2012 167
GANYMED Pharmaceuticals AG, H1 2012 168
Abiogen Pharma S.p.A., H1 2012 169
Glycotope GmbH, H1 2012 170
BioNumerik Pharmaceuticals, Inc., H1 2012 171
Indena S.p.A., H1 2012 172
Alethia Biotherapeutics Inc., H1 2012 173
Coronado Biosciences, Inc., H1 2012 174
Heat Biologics, Inc., H1 2012 175
MacroGenics, Inc., H1 2012 176
Fresenius Biotech GmbH, H1 2012 177
Azaya Therapeutics, Inc., H1 2012 178
CanBas Co., Ltd., H1 2012 179
Merrimack Pharmaceuticals, Inc., H1 2012 180
Spirogen Ltd., H1 2012 181
Neotropix, Inc., H1 2012 182
Conatus Pharmaceuticals Inc., H1 2012 183
CritiTech, Inc., H1 2012 184
BioCancell Therapeutics, Inc., H1 2012 185
Endocyte, Inc., H1 2012 186
Advenchen Laboratories, LLC, H1 2012 187
Onconova Therapeutics, Inc, H1 2012 188
MolMed S.p.A., H1 2012 189
Immunotope, Inc., H1 2012 190
Esperance Pharmaceuticals, Inc., H1 2012 191
Bolder Biotechnology, Inc., H1 2012 192
BiPar Sciences, Inc., H1 2012 193
ImmunoVaccine Technologies Inc., H1 2012 194
Welichem Biotech Inc., H1 2012 195
Angstrom Pharmaceuticals, Inc., H1 2012 196
Vaccinogen, Inc., H1 2012 197
Cancer Vaccines Limited, H1 2012 198
NewLink Genetics Corporation, H1 2012 199
TVAX Biomedical, LLC, H1 2012 200
Quintessence Biosciences, Inc., H1 2012 201
arGEN-X BV, H1 2012 202
Kinex Pharmaceuticals, LLC, H1 2012 203
Tigris Pharmaceuticals, Inc., H1 2012 204
Viventia Biotechnologies Inc., H1 2012 205
TRACON Pharmaceuticals, Inc., H1 2012 206
Advanced Cancer Therapeutics, H1 2012 207
Oncolix, Inc., H1 2012 208
OHR Pharmaceutical Inc., H1 2012 209
RECEPTA Biopharma S.A., H1 2012 210
Kyowa Hakko Kirin Pharma, Inc., H1 2012 211
Vaxonco, H1 2012 212
Sentinel Oncology Limited, H1 2012 213
Mebiopharm Co., Ltd., H1 2012 214
VectorLogics, Inc., H1 2012 215
ISA Pharmaceuticals B.V., H1 2012 216
Gradalis Inc., H1 2012 217
Oncozyme Pharma Inc., H1 2012 218
Assessment by Monotherapy Products, H1 2012 219
Assessment by Combination Products, H1 2012 220
Assessment by Stage and Route of Administration, H1 2012 223
Assessment by Molecule Type, H1 2012 226
Ovarian Cancer Therapeutics – Drug Profile Updates 367
Ovarian Cancer Therapeutics – Discontinued Products 375
Ovarian Cancer Therapeutics – Dormant Products 381
List of Figures
Number of Products under Development for Ovarian Cancer, H1 2012 23
Products under Development for Ovarian Cancer – Comparative Analysis, H1 2012 24
Products under Development by Companies, H1 2012 25
Products under Investigation by Universities/Institutes, H1 2012 35
Late Stage Products, H1 2012 46
Mid Clinical Stage Products, H1 2012 47
Early Clinical Stage Products, H1 2012 48
Discovery and Pre-Clinical Stage Products, H1 2012 49
Assessment by Monotherapy Products, H1 2012 219
Assessment by Combination Products, H1 2012 220
Assessment by Route of Administration, H1 2012 221
Assessment by Stage and Route of Administration, H1 2012 222
Assessment by Molecule Type, H1 2012 224
Assessment by Stage and Molecule Type, H1 2012 225
|
